News

Qilu Antibiotics passed US FDA inspection with no 483 observation

ABOUT US

News

Qilu Antibiotics passed US FDA inspection with no 483 observation

Release time：

2018-08-16

Qilu Pharmaceutical announces that its subsidiary Qilu Antibiotics successfully passed the US FDA inspection with no 483 observation. The inspection commenced on August 8, 2018 and was completed on August 16, 2018.

Qilu Antibiotics is the world’s major supplier of Cephalosporin products with the capacity of 2000 tons/year. Products have been exported to more than 40 countries, including US, EU, Japan, Korea, etc.

Qilu Launches Generic Aloxi® Injection in the US

Piperacillin Sodium/Tazobactam Sodium for injection approved by US FDA

Related News

Qilu Pharmaceutical ranks No.3 in the list of "Top 100 Enterprises in Chinese Pharmaceutical industry”

2024-09-30

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Qilu Pharmaceutical launched the first innovative drug in China

2023-09-01

Qilu Pharmaceutical Group Awarded as Socially Responsible Enterprises (Entrepreneurs) in 2022

2023-04-04

Qilu Pharmaceutical ranks No.5 in the list of "Top 100 Enterprises in Chinese Pharmaceutical Industry”